David Arkowitz Biography and Net Worth

Director of iBio

David Arkowitz brings over 30 years of experience in finance, operations, business development, and commercial leadership within the life sciences and biotech sectors. He is currently the CFO of Alkeus Pharmaceuticals, a privately held late-stage biopharma company focused on preserving sight in individuals with retinal diseases. Before joining Alkeus, Mr. Arkowitz was EVP, CFO, and Head of Business Development at Seres Therapeutics. He also served as CFO at Flexion Therapeutics, which was acquired by Pacira Biosciences, and as COO and CFO of Visterra, acquired by Otsuka Pharmaceuticals. Earlier in his career, he held CFO roles at Mascoma, AMAG Pharmaceuticals and Idenix Pharmaceuticals, where he also contributed in various leadership capacities. Mr. Arkowitz spent over 13 years at Merck, where he was VP and Controller of the U.S. pharmaceutical business, Controller of the global R&D division, and CFO of Merck’s Canadian subsidiary. In addition to his executive roles, Mr. Arkowitz serves on the board of directors of Kineta and has previously been a board member of F-star Therapeutics, Yumanity Therapeutics, Spring Bank Pharmaceuticals, Proteostasis Therapeutics, Aegerion Pharmaceuticals, and ImpactRx.

What is David Arkowitz's net worth?: The estimated net worth of David Arkowitz is at least $23.25 thousand as of January 10th, 2025. Arkowitz owns 18,382 shares of iBio stock worth more than $23,253 as of September 18th. This net worth evaluation does not reflect any other investments that Arkowitz may own. Learn More about David Arkowitz's net worth.
How do I contact David Arkowitz?: The corporate mailing address for Arkowitz and other iBio executives is 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737. iBio can also be reached via phone at (302) 355-0650 and via email at [email protected]. Learn More on David Arkowitz's contact information.
Has David Arkowitz been buying or selling shares of iBio?: David Arkowitz has not been actively trading shares of iBio within the last three months. Most recently, on Friday, January 10th, David Arkowitz bought 18,382 shares of iBio stock. The stock was acquired at an average cost of $2.72 per share, with a total value of $49,999.04. Following the completion of the transaction, the director now directly owns 18,382 shares of the company's stock, valued at $49,999.04. Learn More on David Arkowitz's trading history.
Are insiders buying or selling shares of iBio?: In the last twelve months, iBio insiders bought shares 2 times. They purchased a total of 37,171 shares worth more than $75,085.42. The most recent insider tranaction occured on March, 19th when CFO Felipe Duran bought 24,835 shares worth more than $50,166.70. Insiders at iBio own 1.6% of the company. Learn More about insider trades at iBio.
Information on this page was last updated on 3/19/2026.

David Arkowitz Insider Trading History at iBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/10/2025	Buy	18,382	$2.72	$49,999.04	18,382

David Arkowitz Buying and Selling Activity at iBio

iBio Company Overview

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Today's Range

Now: $1.29

$1.24

$1.30

50 Day Range

MA: $1.37

$1.18

$1.51

2 Week Range

Now: $1.29

$0.77

$3.82

Volume

164,956 shs

Average Volume

1,148,913 shs

Market Capitalization

$82.64 million

P/E Ratio

N/A

Dividend Yield